Hikma ‘skinny’ label does not infringe Amarin patents

Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

More on this story

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

More on this story

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Hikma ‘skinny’ label does not infringe Amarin patents

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features